Key Points
- Insider selling: Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics for $20,993.40, reducing his ownership by 15.95% to 8,617 shares. The sale follows several other disposals by Bizily since August.
- Analyst sentiment remains positive: The stock has a consensus “Moderate Buy” rating from analysts, with an average price target of $28.90 versus a reported share price of $13.10.
- Financial performance remains challenged: 4D Molecular Therapeutics reported a quarterly loss of $1.04 per share, slightly below estimates, despite revenue of $3.78 million. The clinical-stage biotechnology company is developing gene therapies, including 4D-150 for retinal diseases.
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) insider Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock in a transaction dated Friday, October 16th. The stock was sold at an average price of $12.84, for a total value of $20,993.40. Following the completion of the sale, the insider owned 8,617 shares of the company's stock, valued at approximately $110,642.28. The trade was a 15.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Scott Bizily also recently made the following trade(s):
- On Wednesday, September 16th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $13.65, for a total value of $22,317.75.
- On Tuesday, September 1st, Scott Bizily sold 584 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $14.00, for a total transaction of $8,176.00.
- On Thursday, August 13th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $12.00, for a total transaction of $19,620.00.
- On Monday, August 17th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $12.20, for a total transaction of $19,947.00.
4D Molecular Therapeutics Stock Up 6.6%
Shares of NASDAQ FDMT opened at $13.10 on Wednesday. 4D Molecular Therapeutics, Inc. has a 1 year low of $6.96 and a 1 year high of $16.93. The firm's 50-day moving average is $14.05 and its 200-day moving average is $11.57. The company has a current ratio of 8.03, a quick ratio of 8.03 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $723.64 million, a PE ratio of -4.98 and a beta of 2.75.
4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.02). The business had revenue of $3.78 million for the quarter, compared to analyst estimates of $3.62 million. 4D Molecular Therapeutics had a negative return on equity of 41.33% and a negative net margin of 194.74%. Equities analysts expect that 4D Molecular Therapeutics, Inc. will post -4.14 EPS for the current year.
Analysts Set New Price Targets
A number of analysts have commented on the stock. Bank of America lifted their target price on shares of 4D Molecular Therapeutics from $29.00 to $33.00 and gave the stock a "buy" rating in a report on Tuesday, September 29th. Cantor Fitzgerald raised 4D Molecular Therapeutics from a "neutral" rating to an "overweight" rating and set a $20.00 price target on the stock in a research note on Monday, September 14th. The Goldman Sachs Group reissued a "buy" rating and issued a $32.00 price target on shares of 4D Molecular Therapeutics in a research note on Thursday, August 13th. B. Riley Financial restated a "buy" rating on shares of 4D Molecular Therapeutics in a research report on Monday, August 17th. Finally, Chardan Capital decreased their price objective on 4D Molecular Therapeutics from $26.00 to $25.00 and set a "buy" rating for the company in a research note on Tuesday, October 6th. Ten equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $28.90.
Read Our Latest Stock Analysis on 4D Molecular Therapeutics
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Toth Financial Advisory Corp acquired a new position in 4D Molecular Therapeutics in the third quarter valued at about $29,000. Legal & General Group Plc bought a new stake in shares of 4D Molecular Therapeutics in the second quarter worth about $59,000. Susquehanna Fundamental Investments LLC bought a new stake in shares of 4D Molecular Therapeutics in the second quarter worth about $148,000. The Manufacturers Life Insurance Company bought a new stake in shares of 4D Molecular Therapeutics in the second quarter worth about $166,000. Finally, Sei Investments Co. raised its position in shares of 4D Molecular Therapeutics by 8.9% during the first quarter. Sei Investments Co. now owns 12,862 shares of the company's stock worth $120,000 after purchasing an additional 1,050 shares during the period. 99.27% of the stock is currently owned by institutional investors.
4D Molecular Therapeutics Company Profile
(
Get Free Report)
4D Molecular Therapeutics, Inc is a clinical-stage biotechnology company focused on developing gene therapies for serious diseases. The company uses its Therapeutic Vector Evolution platform to engineer adeno-associated virus (AAV) vectors designed to deliver genetic medicines to specific tissues, including the eye and lungs.
Its investigational pipeline includes 4D-150, an intravitreal gene therapy being developed for retinal diseases such as wet age-related macular degeneration and diabetic macular edema.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
